Symbiosis Pharmaceutical Services, one of the leading Contract Manufacturing Organisation (CMO) specializing in sterile GMP manufacturing of biopharmaceuticals, has been recognized by EcoVadis, a global provider of business sustainability ratings.

The company says it has been awarded a Committed Badge through the EcoVadis recognition system for its efforts in carbon reduction and alignment with the Science Based Targets initiative (SBTi).

This recognition highlights Symbiosis’ commitment to sustainability in the pharmaceutical supply chain by integrating environmental, social, and governance (ESG) principles across its operations.

As part of its sustainability action plan, Symbiosis has calculated its carbon footprint and set clear reduction targets. The company is introducing several strategic initiatives to lower its environmental impact, including the use of 100% renewable electricity to power operations, heat recovery systems, and air source heat pumps to enhance energy efficiency. Additionally, Symbiosis is implementing water conservation through recirculation.

These initiatives are expected to save a projected CO₂ reduction of 151.7 tonnes, and the company believes it will achieve a 37% reduction in emissions after transitioning to 100% renewable energy in 2025.

“As we continue to expand our world-class sterile manufacturing operations, sustainability remains a key consideration at the heart of our growth planning,” said Colin MacKay, CEO at Symbiosis.

“This recognition from EcoVadis acknowledges our practical commitment to environmental responsibility, and we are proud to take meaningful steps in support of a more sustainable biopharmaceutical industry.”

“With demand for our automated sterile drug manufacturing capacity increasing, the company remains focused on minimizing its environmental impact while delivering high-quality, GMP-compliant solutions to clients around the world,” MacKay added.

Headquartered in Stirling, UK, Symbiosis specializes in the sterile manufacture (fill/finish) of pharmaceuticals and biopharmaceuticals for clinical trials and commercial markets. The company most recently reported a successful routine FDA inspection of its facilities and quality system.

The company says it continues its physical and operational expansion with the completion of a new state-of-the-art automated sterile GMP manufacturing facility near its existing facilities in Stirling, UK. This expansion will increase the company’s sterile manufacturing capabilities, enabling it to support a growing number of clients globally through the clinical and commercial injectable drug product lifecycle challenges.